提示：
1、该刊为只有国际刊号。
2、投稿方式：邮箱投稿。
3、刊内网址：http://www.clincancerbull.com/
4、官网邮箱：zsccb@vip.163.com
5、官网电话：021-51217570
6、出刊日期：季刊，逢季首月出版。
7、2022—2024年期间所有论文的稿件加工处理费（Article Processing Charges，APC）一律免除（微信公众号信息）。
2022年6月17日星期五
Clinical Cancer Bulletin创刊号正式在线出版
【微信公众号“复旦大学中山医院中国临床医学”信息】
复旦大学中山医院中国临床医学 2022-06-07
经过主编樊嘉院士及国际编委会团队一年多的辛勤筹备和不懈努力，Clinical Cancer Bulletin|CCB (online ISSN 2791-3937) 创刊号于2022年6月1日正式在线出版。在此，向关心和支持CCB创办和发展的专家团队及编辑出版界同仁表示衷心感谢和崇高敬意！
CCB创刊号共在线发表7篇论文，包括主编创刊词（Inaugural Editorial）、研究论文（Research Article）、综述（Review Article）、热点透视/观点（Perspective）、评论（Comments）等栏目，内容涉及肝癌、肺癌、血液系统肿瘤的临床诊治新进展、人工智能在肿瘤诊治中的应用前景以及肿瘤靶向和免疫治疗药物研发进展和临床研究热点剖析。论文来自国内复旦大学、海军军医大学、中国医科大学、温州医科大学以及德国慕尼黑工业大学伊萨尔河畔临床教学中心等机构的杰出肿瘤学研究团队，内容精彩纷呈，不容错过。全文免费在线开放获取（Open Access），欢迎广大读者下载阅读，下载阅读网址 http://www.clincancerbull.com/en/article/current 。
CCB聚焦中国肿瘤学研究，重点关注新疗法、新药物临床试验研究、肿瘤多学科诊疗研究、医工交叉及跨学科合作在癌症防治中的应用等领域。第2期预计于2022年9月出版，特别关注“新冠疫情下肿瘤患者管理” “肿瘤心脏病学研究进展”，欢迎广大癌症防治研究领域学者及临床肿瘤专家就相关专题积极组稿、投稿。
CCB发表论文类型包括：社论（Editorial）、研究论文（Research Article）、综述（Review Article）、热点透视/观点（Perspective）、评论（Comments）、致编辑的信（Letter）等。2022—2024年期间所有论文的稿件加工处理费（Article Processing Charges，APC）一律免除。
CCB论文投稿采用eZ Submit模式，投稿时文章格式不限，正式接收后再按本刊要求修改。目前本刊采用E-mail邮箱接受投稿，欢迎广大肿瘤学专家学者积极投稿。
邮箱：E-mail: zsccb@vip.163.com
网址：www.clincancerbull.com
Clinical Cancer Bulletin正式创刊，欢迎投稿！
【微信公众号“复旦大学中山医院中国临床医学”信息】
CCB编辑部 复旦大学中山医院中国临床医学 2022-05-18
肿瘤学新刊Clinical Cancer Bulletin（《临床癌症通报》）正式创刊，并将于2022年6月正式在线出版，欢迎全球临床肿瘤研究专家及癌症防治学者积极投稿！
Clinical Cancer Bulletin（CCB）是由复旦大学附属中山医院主办，经严格同行评议、开放获取（OA）、在线出版的临床肿瘤学季刊，发表肿瘤转化医学、外科手术学、放化疗、靶向治疗、免疫治疗、新药研发及癌症防治研究领域高质量学术论文，报道肿瘤防治全流程的新理念、新技术、新方法，打造全球化的临床癌症研究交流平台，建设一流肿瘤学学术期刊，力争为全球肿瘤学专家提供最新的权威肿瘤学研究资讯，助力攻克癌症，造福全球肿瘤患者。
CCB主编由中国科学院院士复旦大学附属中山医院院长樊嘉教授担任，邀请来自全球各地近30名肿瘤学专家学者担任副主编及编委，确保期刊的学术质量。CCB组建了强大的审稿专家及学术编辑团队，为所有作者提供高效的稿件处理及出版服务，对具有创新价值的论文开放快速发表通道，最快可以一周内接受。CCB将对发表后的论文提供多种形式的增强出版和推广服务，提高论文的显示度和影响力。
CCB发表论文类型包括：社论（Editorial）、研究论文（Research Article）、综述（Review Article）、观点（Perspective）、评论（Comments）、致编辑的信（Letter）等。2022—2024年期间所有论文的稿件加工处理费（Article Processing Charges，APC）一律免除。
CCB论文投稿采用eZ Submit模式，投稿时文章格式不限，正式接收发表后再按本刊要求修改。目前本刊采用E-mail邮箱接受投稿，欢迎广大肿瘤学专家学者积极投稿。
邮箱：E-mail: zsccb@vip.163.com
网址：www.clincancerbull.com
作者须知Instruction for Authors
【官网信息】
Clinical Cancer Bulletin (CCB) was launched in 2022 by its founding Editor-in-Chief, Prof. Jia Fan, CAS member, a well-known hepatobiliary surgery expert and cancer researcher in Zhongshan Hospital, Fudan University. CCB is an international, strict, peer-reviewed open access journal covering international issues relevant to clinical cancer specialists worldwide, and is published quarterly in English. A strict and rigorous anonymous peer-review procedure ensures the quality and equal standing of articles submitted by clinical cancer researchers.
CCB is willing to become the world’s leading clinical cancer periodical publishing high-quality, peer-reviewed research findings (especially reports from clinical trials), reviews, perspectives, letters, and guideline & consensus reports, and ensuring the information is presented in understandable, clinically useful formats.
1 General
1.1Aim & Scope
CCB strives to report original, innovative, high-quality, and timely contents in clinical oncology and to deliver the most credible, authoritative cancer research resources to clinical cancer specialists.
Manuscripts are welcome from all over the world on all aspects of clinical oncology. It mainly presents reports on clinical oncology, translational oncology, cancer epidemiology & prevention, pharmacology in precision oncology, and biomarkers research of oncology and immunotherapy. Original research articles and reviews are preferred, and perspectives, short communications, guideline & consensus reports, and letters to the editor are also accepted.
1.2 Ethics
All articles and researches submitted to CCB should follow the Committee of Publication Ethics (COPE) guidelines (https://publicationethics.org/guidance/Guidelines). For the reports concerning experiments on human subjects, a statement that the subject has signed an informed consent should be included in the Materials section. Human experiments should be performed only in accordance with the ethical standards provided by the responsible committee of the institution and in accordance with the World Medical Association Declaration of Helsinki (revised in 2013, https://www.wma.net/policies-post/wma-declaration- of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). Animal experiments should be done in accordance with the instructions for the care and use provided by the institution at which the research was carried out.
1.3 Style & Format
All articles submitted to CCB are accepted on the understanding that they have not been published or submitted elsewhere, unless the Editor is clearly so-informed. Previous presentation at a scientific meeting, and/or publication of the abstract in conjunction with the meeting, does not preclude publication of the article; however, this information must be disclosed in a cover letter at the time of submission. Previously published articles, including those published in non-English-language journals, are not accepted. CCB does not accept manuscript submissions involving human subjects (or their medical records) that have been previously posted to preprint servers.
Manuscripts should follow the style of the Vancouver Agreement detailed in the International Committee of Medical Journal Editors' revised "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals" (http://www.icmje.org/recommendations/, Updated December 2019). The manuscript should be kept as concise as possible. Use specific, concrete words and simple sentences instead of vague, general ones wherever possible. Authors should consult a recent issue of Clinical Cancer Bulletin to get familiar with the general layout and various elements in an article. All clinical trials must have been registered in a public trials registry such as www.clinicaltrials.gov in accordance with the International Committee of Medical Journal Editors (ICMJE) guidelines for trial registration. Additionally, all reports of randomized controlled trials must have been prospectively registered in a trial registry in order to be considered for publication.
1.4 Clinical Data
If requested by the Editor-in-Chief, authors must make all data supporting the findings described in their manuscript fully available without restriction for examination in a timely fashion.
2 Editorial Process
2.1 Easy Submission
Authors may submit works by the following way: E-mail the manuscript as an attached MS word file to zsccb@vip.163.com.
CCB has adopted a format-free submission policy (eZ Submit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, word limits, order of components, etc.). As long as the required information is presented (cover letter, title page, abstract, references, CONSORT diagram for randomized studies, protocol for randomized and interventional trials, etc.), the manuscript will be considered by the editors.
CCB is conscious of the time spent by authors on reformatting manuscripts to the specifications of journals. eZ Submit allows authors to submit their new manuscripts without having to adhere to such requirements. The adoption of this policy will help authors and researchers save time and use their resources more efficiently.
2.2 Review
All the manuscripts that adhere to our Style and Preparation of Manuscripts are subject to peer-review. Some of them are rejected immediately after an in-house review. The rejection at this stage is due to insufficient originality, serious scientific flaws or absence of messages. The remaining articles are sent to experts in the concerned subjects and the final decision is made at the manuscript conference attended by our editor-in-chief and some members of the editorial board. The whole process will take approximately 2 months. Then the decision on the manuscript, whether it is accepted, rejected, or requires revision, will be sent to the authors.
2.3 Revision
The accepted manuscripts should go through editorial revision to comply with the requirements of the reviewers' comments, language standards and the style of the journal. The rejected manuscripts are not returned to the authors, but the author will receive a decision letter with the reviewers' comments.
2.4 Proofs
Corrections on the proof should be restricted to errors only and no substantial additions or deletions should be made.
2.5 Open Access Publication and Creative Commons Licensing
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
2.6 Payment
All papers published in CCB are free of any publication fee.
3 Preparation of Manuscripts
All submissions should include the following:
● Title Page. This should include: the full title of the paper, the name, institution and e-mail address of all contributing authors.
● Abstract. This should be submitted on a separate page and should describe in fewer than 350 words exactly what was done, the results obtained, and the conclusions drawn. Following the abstract, and on the same page, a list of key words (up to seven) for coding and indexing should be supplied.
● Text.
● Grants and other acknowledgements.
● Disclosure of potential conflicts of interest.
● References.
● Charts, graphs, tables, and photographs.
● Figure legends.
A summary of technical requirements for preparing the manuscript is provided below:
● The whole text must be double-spaced with ample margins. All pages should be numbered consecutively starting with the title page as page 1.
● Use American English throughout the paper.
● Use at least 11 point font size (Times New Roman or Arial).
● Conventional units are preferred with SI units in parentheses, if available. The metric system is preferred for the expression of length, area, mass and volume.
● Use nonproprietary names of drugs, devices and other products.
Manuscripts not fulfilling the technical requirements shall be returned to the authors without initiating the peer-review process.
Abstract & Keywords The abstract should state the purpose of the study, basic methodology, main findings (specific data and statistical significance) and key conclusion(s). Below the abstract, authors should provide 3-5 key words for indexing; terms from the Medical Subject Headings (MESH) list of Index Medicus should be used.
Introduction The introduction must clearly state the question that the author(s) tried to answer in the study. It may be necessary to briefly review the relevant literature. Only cite those references that are essential to justifying the proposed study.
Methods The methods section should describe how the study was designedand carried out and how the data were analyzed. For standard methods, appropriate references are sufficient, but if standard methods are modified these should be clearly brought out. Authors should provide complete details of any new methods or apparatus used (manufacturer's name and address).
Results This section should include only relevant, representative data but not all information collected during the study. Major findings should be presented clearly and concisely. Text, tables, and illustrations should be used sensibly by avoiding repeating in the text all the data depicted in the tables or illustrations but emphasizing or summarizing only important observations.
Discussion Discussion ordinarily should not be more than one third of the total length of the manuscript. This section should include a summary of the major findings, their relationship to other similar studies, limitations of the methods and implication of these findings to future research. Conclusions should be linked to the goals of the study. Statements which are not completely supported by the data should be avoided.
Disclosure of potential conflicts of interest Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of a real or perceived conflict of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate.
References References should be numbered consecutively in the order in which they are first mentioned in the text. References are identified in text, tables and legends by Arabic numerals in parentheses. The titles of journals should be abbreviated according to the style used in Index Medicus. It is required not to use abstracts, unpublished observations and personal communications as references. References to papers accepted but not yet published should be designated as "in press". Journal article: List all authors when there are 6 or less. When the number of authors is 4 or more, only list the first 3 and add “et al.”.
Tables Tables must be numbered consecutively in the order of their first citation in the text, with a brief but self-explanatory title for each. Each column should have a short or abbreviated heading. Explanatory matters are placed in footnotes. In the footnotes all nonstandard abbreviations that are used in each table should be explained adequately. Statistical measures of variations should be identified.
Figures and illustrations Figures and images should be labeled sequentially, numbered and cited in the text. The use of three-dimensional histograms is strongly discouraged when the addition of the third dimension gives no extra information. If a table or figure has been published before, the authors must obtain a written permission to reproduce the material in both print and electronic formats from the copyright owner and submit it with the manuscript. Legends must be submitted for all figures. They should be brief and specific. Use scale markers in the image for electron micrographs, and indicate the type of stain used. Authors will be required to pay the cost of color illustrations published in print.
Abbreviations and Symbols Only standard abbreviations are used in the text while avoiding abbreviations in the title. The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement. Year, month, day, hour, minute and second should be abbreviated as y, mon, d, h, min, and s in tables respectively.
4 Contact informaiton for the Editorial Office
Welcome to contribute to Clinical Cancer Bulletin!
For any question on the submission, please contact the Editorial Office.
Address: Room 516, Building 18, 180 Fenglin Road, Xuhui District, Shanghai 200032, China
Tel: 8621-51217570
E-mail: zsccb@vip.163.com
